-
公开(公告)号：US09441034B2
公开(公告)日：2016-09-13
申请号：US12934756
申请日：2009-03-27
申请人： Pallavur V. Sivakumar , Debra G. Gilbertson , Marshall D. Snavely , George R. Mabry , Eugene C. Yi , Yue Yao , Scott R. Presnell
发明人： Pallavur V. Sivakumar , Debra G. Gilbertson , Marshall D. Snavely , George R. Mabry , Eugene C. Yi , Yue Yao , Scott R. Presnell
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92
摘要： Disclosed are antagonists of PDGF receptor β (PDGFRβ) and VEGF-A, including neutralizing anti-PDGFRβ and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRβ and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRβ and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRβ and/or VEGF-A antagonist.
摘要翻译： 公开了PDGF受体β（PDGFRβ）和VEGF-A的拮抗剂，包括中和抗PDGFRβ和抗VEGF-A抗体，以及相关的组合物和方法。 本文公开的抗PDGFRβ和抗VEGF-A抗体包括能够结合和中和PDGFRβ和VEGF-A两者的双特异性抗体。 还公开了使用PDGFRβ和/或VEGF-A拮抗剂治疗新生血管性疾病如癌症或新生血管性眼病的方法。
-
公开(公告)号：US20110177074A1
公开(公告)日：2011-07-21
申请号：US12934756
申请日：2009-03-27
申请人： Pallavur V. Sivakumar , Debra G. Gilbertson , Marshall D. Snavely , George R. Mabry , Eugene C. Yi , Yue Yao , Scott R. Presnell
发明人： Pallavur V. Sivakumar , Debra G. Gilbertson , Marshall D. Snavely , George R. Mabry , Eugene C. Yi , Yue Yao , Scott R. Presnell
IPC分类号： A61K39/395 , C07K16/22 , C07H21/04 , C12N15/63 , C12N5/071 , C12P21/02 , A61P9/00 , A61P35/00 , A61P27/02 , A61P27/06
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92
摘要： Disclosed are antagonists of PDGF receptor β (PDGFRβ) and VEGF-A, including neutralizing anti-PDGFRβ and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRβ and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRβ and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRβ and/or VEGF-A antagonist.
摘要翻译： 公开了PDGF受体拮抗剂 （PDGFR＆bgr）和VEGF-A，包括中和抗PDGFR＆bgr; 和抗VEGF-A抗体，以及相关的组合物和方法。 抗PDGFR＆bgr; 和本文公开的抗VEGF-A抗体包括能够结合和中和PDGFR和bgr的双特异性抗体; 和VEGF-A。 还公开了使用PDGFR和bgr治疗新生血管性疾病如癌症或新生血管性眼病的方法; 和/或VEGF-A拮抗剂。
-
公开(公告)号：US08969518B2
公开(公告)日：2015-03-03
申请号：US12943256
申请日：2010-11-10
申请人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
发明人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
IPC分类号： C07K14/00 , C07K14/705 , C07K16/28 , A61K39/00
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译： 公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。 还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。 还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。
-
公开(公告)号：US20090220502A1
公开(公告)日：2009-09-03
申请号：US12246214
申请日：2008-10-06
申请人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
发明人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao , Pallavur V. Sivakumar
IPC分类号： A61K39/395 , C07K14/00 , C07H21/00 , C12N15/74 , C12N1/00 , C07K16/18 , A61K38/16 , G01N33/53 , A61P35/00
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译： 公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。 还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。 还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。
-
公开(公告)号：US20090191214A1
公开(公告)日：2009-07-30
申请号：US12330334
申请日：2008-12-08
申请人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
发明人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
IPC分类号： A61K39/395 , C07K16/00 , C12N5/12 , A61P17/06 , A61P37/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
摘要翻译： 提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。 这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组IL-21蛋白和/或肽区的能力。 这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞，TH细胞或TH17细胞介导的疾病。
-
公开(公告)号：US08361470B2
公开(公告)日：2013-01-29
申请号：US13474001
申请日：2012-05-17
申请人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
发明人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells, TH cells or TH17 cells.
摘要翻译： 提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。 这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组IL-21蛋白和/或肽区的能力。 这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞，TH细胞或TH17细胞介导的疾病。
-
公开(公告)号：US08241629B2
公开(公告)日：2012-08-14
申请号：US12971495
申请日：2010-12-17
申请人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
发明人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
-
公开(公告)号：US07883700B2
公开(公告)日：2011-02-08
申请号：US12330334
申请日：2008-12-08
申请人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
发明人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
IPC分类号： A61K39/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.
摘要翻译： 提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。 这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组IL-21蛋白和/或肽区的能力。 这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞，TH细胞或TH17细胞介导的疾病。
-
公开(公告)号：US07858759B2
公开(公告)日：2010-12-28
申请号：US12246214
申请日：2008-10-06
申请人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao
发明人： Cameron S. Brandt , Jacob J. Kennedy , Wenfeng Xu , Eugene C. Yi , Brian A. Fox , Zeren Gao
IPC分类号： C07K16/00
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译： 公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。 还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。 还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。
-
公开(公告)号：US20100041873A1
公开(公告)日：2010-02-18
申请号：US12483098
申请日：2009-06-11
申请人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
发明人： Stephen R. Jaspers , Mark W. Rixon , Stacey R. Dillon , Frederick J. Ramsdell , Cecile M. Krejsa , Eugene C. Yi
IPC分类号： C07K16/00
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , Y10S530/809
摘要： Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinat IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells THcells or TH17 cells.
摘要翻译： 提出人抗人IL-21单克隆抗体和产生它们的杂交瘤。 这些抗体中的某些具有结合天然人IL-21，人IL-21的突变重组IL-21蛋白和/或肽区的能力。 这些人抗IL-21抗体可用于治疗自身免疫性和炎性疾病，特别是由T滤泡辅助细胞，B细胞，TH细胞或TH17细胞介导的疾病。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.061 秒)
